Showing 8621-8630 of 10254 results for "".
- Metal Implants May Cause Nickel Hypersensitivityhttps://practicaldermatology.com/news/metal-implants-may-cause-nickel-hypersensitivity/2461614/Dermatologists are seeing more patients concerned about a possible skin hypersensitivity to the nickel or other metals used in implanted medical devices. Millions of people in the U.S. report having a metal allergy, and current estimates state that 10 percent of Americans will receive a
- Bioelectric V.Dox Technology Reduces Biofilm Infection in Burn Woundshttps://practicaldermatology.com/news/bioelectric-vdox-technology-reduces-biofilm-infection-in-burn-wounds/2461611/Vomaris Innovations, Inc. bioelectric V.Dox Technology prevents and reduces biofilm infection in burn wounds, a new study shows. The study appears in Advances in Wound Care. The collaborative research was led by Rodney Chan, M.D, a plastic and reco
- Rosacea Pipeline Update: Tarsus Starts Phase 2A Trial of TP-04 in PPRhttps://practicaldermatology.com/news/rosacea-pipeline-update-tarsus-starts-phase-2a-trial-of-tp-04-in-ppr/2461604/
- LEO Pharma, ICON Enter a Strategic Partnership to Propel Clinical Trial Execution within Dermatologyhttps://practicaldermatology.com/news/leo-pharma-icon-enter-a-strategic-partnership-to-propel-clinical-trial-execution-within-dermatology/2461602/LEO Pharma and
- Landmark Data: Neoadjuvant Pembrolizumab Improves Outcomes for High-risk Melanoma Patientshttps://practicaldermatology.com/news/landmark-data-neoadjuvant-pembrolizumab-improves-outcomes-for-high-risk-melanoma-patients/2461589/Patients with high-risk melanoma who received pembrolizumab both before and after surgery had a significantly lower risk of their cancer recurring than patients who received the drug only after surgery. These results, published today in the
- Celluma Light Therapy Headquarters Moves to Tustin, Californiahttps://practicaldermatology.com/news/celluma-light-therapy-headquarters-moves-to-tustin-calif/2461570/BioPhotas, Inc., the maker of the Celluma Series of light therapy devices, is moving its corporate headquarters and manufacturing operations from Anaheim to Tustin, Calif. The new headquarters boasts 25,000 square feet of office and warehouse space, facilitating continued gro
- Relief Therapeutics Enrolls First Patients in Proof-of-Concept Trial of Epidermolysis Bullosa Treatmenthttps://practicaldermatology.com/news/relief-therapeutics-enrolls-first-patients-in-proof-of-concept-trial-of-epidermolysis-bullosa-treatment/2461563/Relief Therapeutics announced the first three patients have been enrolled in a proof-of-concept, investigator-initiated study to evaluate RLF-TD011 as a treatment for epidermolysis bullosa (EB). The primary aim of the study will be to assess changes in the skin microbiome (Staphylococcu
- Povorcitinib Produces Lasting Results in HShttps://practicaldermatology.com/news/povorcitinib-produces-lasting-results-in-hs/2461557/Longer-term treatment with povorcitinib 75 mg resulted in sustained and durable efficacy across all treatment arms in a phase 2 study of hidradenitis suppurativa (HS) patients. Povorcitinib is an oral JAK1 inhibitor. These data were presented as an oral presentation at th
- Meet FACE by Galdermahttps://practicaldermatology.com/news/meet-face-by-galderma/2461524/Galderma is launching FACE by Galderma, an app that simulates the results of injectable treatments in real time using digital facial assessment. The technology was unveiled at the International Master Course on Aging Science (IMCAS) World Congress 2023 in Paris. FACE by Galder
- Revealed: The Genetic Basis of 13 Pigment Traits and Their Relationship with Diseaseshttps://practicaldermatology.com/news/revealed-the-genetic-basis-of-13-pigment-traits-and-their-relationship-with-diseases/2461515/Researchers have uncovered the genetic basis of 13 pigment traits and their association with diseases. Using the GCAT cohort, researchers built a comprehensive analysis strategy leading to the identification of phototype associated-diseases in a total of nearly 20,000 Ca